Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSO-0205
- Development stage
- Preclinical
- Lead developer
- Envisagenics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
SSO-0205 is a preclinical splice-switching antisense oligonucleotide (SSO) developed by Envisagenics using its AI/ML-driven SpliceCore platform. It is designed to target and promote the inclusion of exon 13 in the neural precursor cell expressed developmentally down-regulated 4-like (NEDD4L) pre-mRNA (NEDD4Le13). In triple-negative breast cancer (TNBC), aberrant skipping of NEDD4L exon 13 is highly prevalent and correlates with poor overall survival. By promoting exon 13 inclusion, SSO-0205 restores the full-length NEDD4L isoform, which downregulates the TGFβ signaling pathway. This leads to decreased cell proliferation, cell cycle arrest in the G1 phase, and a significant reduction in TNBC cell migration and viability.
- Other names
- splice-switching oligonucleotide 0205
02
Targets
E3 ubiquitin-protein ligase NEDD4-like (NEDD4L) exon 13 region in pre-mRNA
Beyond the preview
Go deeper on SSO-0205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSO-0205.